These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23438502)

  • 1. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.
    Morgan CJ; Noronha LA; Muetzelfeldt M; Feilding A; Curran HV
    J Psychopharmacol; 2013 Jun; 27(6):497-506. PubMed ID: 23438502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harms associated with psychoactive substances: findings of the UK National Drug Survey.
    Morgan CJ; Muetzelfeldt L; Muetzelfeldt M; Nutt DJ; Curran HV
    J Psychopharmacol; 2010 Feb; 24(2):147-53. PubMed ID: 19939875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
    Bonnet U; Specka M; Kanti AK; Scherbaum N
    Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
    Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
    Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
    Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts.
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Grigoleit T; Hermle L; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Luckhaus C; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck GA; Wodarz N; McAnally H; Scherbaum N
    Front Psychiatry; 2020; 11():592199. PubMed ID: 33192740
    [No Abstract]   [Full Text] [Related]  

  • 7. Does perception of drug-related harm change with age? A cross-sectional online survey of young and older people.
    Cheeta S; Halil A; Kenny M; Sheehan E; Zamyadi R; Williams AL; Webb L
    BMJ Open; 2018 Nov; 8(11):e021109. PubMed ID: 30401725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
    Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.
    Carhart-Harris RL; Nutt DJ
    J Psychoactive Drugs; 2013; 45(4):322-8. PubMed ID: 24377171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
    Gillet C; Polard E; Mauduit N; Allain H
    Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
    Soussan C; Kjellgren A
    Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Australian drug harms ranking study.
    Bonomo Y; Norman A; Biondo S; Bruno R; Daglish M; Dawe S; Egerton-Warburton D; Karro J; Kim C; Lenton S; Lubman DI; Pastor A; Rundle J; Ryan J; Gordon P; Sharry P; Nutt D; Castle D
    J Psychopharmacol; 2019 Jul; 33(7):759-768. PubMed ID: 31081439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis.
    Al-Banaa I; Hawkins L; Hill SL; Lupton DJ; Jackson G; Sandilands EA; Bradberry SM; Thompson JP; Rushton S; Thomas SHL
    Int J Drug Policy; 2020 Mar; 77():102672. PubMed ID: 32032867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.
    Tanibuchi Y; Matsumoto T; Funada D; Shimane T
    Neuropsychopharmacol Rep; 2018 Dec; 38(4):189-196. PubMed ID: 30341809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
    Kurcevič E; Lines R
    Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.